Th e ERBB receptor family encompasses four trans membrane tyrosine kinases that regulate cell diff erentiation, mitogenesis, survival, and migration. Dysregulated function of these receptor tyrosine kinases has been shown to result in cell transformation and cancer [1] . Th is receptor family includes the epidermal growth factor receptor (EGFR/ERBB1), HER2/ERBB2, HER3/ERBB3, and HER4/ ERBB4. Signaling is triggered by ligand binding to the extracellular domain of EGFR, ERBB3, and ERBB4, resulting in a conformational change in the receptor ectodomains and the dimerization of their cytoplasmic tyrosine kinase domains [2] . Th e receptor-receptor association releases the kinase domain from a default autoinhibited state, leading to transphosphorylation of tyrosine residues in the receptor C-terminus [3] . In turn, these phosphorylated tyrosines become docking sites for the specifi c binding of cytoplasmic signaling proteins containing Src homology-2 and protein tyrosine-binding domains, which then trigger several intracellular signaling pathways associated with cell growth and transformation [4] .
Dimerization and activation of the tyrosine kinase domain of ERBB receptors are highly regulated processes modulated by incompletely understood stimulatory and inhibitory inputs. Recent data suggest that the mere dimerization of EGFR is not suffi cient for their activation [5] . Further, only a fraction of dimerized receptors appears catalytically active, particularly those receptors where the kinase domains are arranged as asymmetric dimers [6, 7] . Th ese data coupled with the observation that receptor dimers may occur in the absence of ligand [5] led to speculation on the presence of cytoplasmic activators that modulate the conversion of these receptor dimers into an active state.
Th e study by Bill and colleagues now reports that cytohesins -guanine-nucleotide exchange factors of the ATP ribosylation factors involved in vesicular traffi cking, cell migration, and cytoskeletal dynamics -facilitate conformational rearrangements in the cytoplasmic domain of ERBB receptors, leading to their activation [8] . Th e cytohesin family consists of four highly homologous proteins, the ubiquitous cytohesin-1, cytohesin-2 (ARNO), cytohesin-3 (Grp), and cytohesin-4, exclusively expressed by immune cells [9] . In this paper, overexpression of ARNO increased EGFR phosphorylation and this eff ect was also seen with a guanine-nucleotide exchange factor-inactive ARNO mutant. Receptor kinase activation was not associated with nor required receptor dimerization or endocytosis, suggesting a possible role for ARNO in asymmetric dimer formation. Using fl uorescence resonance energy transfer and fl uorescently labeled C-terminal EGFR fragments, Bill and colleagues showed that ARNO modulates the inter action between the two receptors in the dimer. Subse quent experiments suggested ARNO binds dimerized EGFR at the kinase or juxtamembrane regions. Similar eff ects were observed on endogenous, already dimerized ERBB2/ERBB3 receptors upon overexpression of ARNO into SKBR3 cells.
Tissue levels of ARNO were evaluated by immunohistochemistry in a cohort of primary lung adenocarcinomas. Staining with ARNO antibodies appeared higher in the cancers compared with normal lung tissues. Further, tissue levels of the cytohesin correlated with levels of P-EGFR, P-ERK, and P-AKT also measured by immunohistochemistry. Inhibition of ARNO with the cytohesin inhibitor SecinH3 or siRNA reduced basal EGFR phosphorylation/activation and growth of EGFRdependent human lung adenocarcinoma cells in vitro.
Abstract
ERBB receptor tyrosine kinases are activated by ligand-induced dimerization followed by activation and transphosphorylation of their intracellular kinase domains. A recent study by Bill and colleagues demonstrates that receptor transphosphorylation can be regulated from inside the cell by members of the cytohesin protein family. These data highlight a novel mechanism of amplifi cation of ERBB receptor signaling output that may contribute to embryogenesis and cancer progression. [10] , which suggests the facilitating role of ARNO on ERBB signaling is not limited to wild-type receptors.
Th ese studies have important implications for cancer biology and therapy as they identify a novel mechanism usurped by transformed cells to amplify ERBB receptor signaling from the cytoplasmic side, and thus increase the number of actively signaling ERBB dimers within the pool of ligand-occupied receptors. As such, over expression of cytohesins would provide a gain-of-fi tness to ERBB signaling output that can be utilized by cancer cells in stressful situations such as fragile windows during metastatic progression and/or when they are exposed to anti-cancer therapies. Th is role of cytohesins may extend to heterologous receptors as suggested by the fact that SecinH3 reduced phosphorylation of IRS-1, a main signal transducer of insulin and IGF-I receptor tyrosine kinases, in H460 lung cancer cells [8] . Future studies should also address whether ARNO overexpression occurs over a wider range of ERBB-dependent cancers. Th e experi ments with ERBB2 gene-amplifi ed and ERBB2-dependent SKBR3 cells suggest that cytohesins can also fi ne tune signaling by (asymmetric) ERBB2/ERBB3 dimers, where the potent ERBB2 kinase activates the catalytically defi cient kinase domain of ERBB3. Th ese heterodimers are the most potent signaling complexes of the ERBB family [4] and are critical for the viability of breast cancer cells with ERBB2 gene amplifi cation [11, 12] . Whether overexpression of cytohesins, by amplifying ERBB signaling, dampens the response to tyrosine kinase inhibitors or receptor antibodies approved for the treatment of ERBBdependent tumors remains to be studied.
In summary, the elegant paper by Bill and colleagues shows that cytohesins promote ERBB receptor signaling by facilitating the formation of asymmetric dimers. For those interested in translational research, these data introduce other assays that can be incorporated into metrics aimed at measuring ERBB receptor output in tumor tissues in situ, such as the tumor content of cytohesins. Finally, the data suggest inside activators of ERBB receptor signal transduction as therapeutic targets that may also need to be interrupted in order to have a maximal eff ect for currently approved anti-ERBB receptor therapies. Abbreviations EGFR, epidermal growth factor receptor; siRNA, small interfering RNA.
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